Background-With the availability of transcatheter aortic valve replacement, management of coronary artery disease in patients with severe aortic stenosis (AS) is posing challenges. Outcomes of percutaneous coronary intervention (PCI) in patients with severe AS and coronary artery disease remain unknown. We sought to compare the short-term outcomes of PCI in patients with and without AS. Methods and Results-From our PCI database, we identified 254 patients with severe AS who underwent PCI between 1998 and 2008. Using propensity matching, we found 508 patients without AS who underwent PCI in the same period. The primary end point of 30-day mortality after PCI was similar in patients with and without severe AS (4.3% [11 of 254] versus 4.7% [24 of 508]; hazard ratio, 0.93; 95% confidence interval, 0.51-1.69; Pϭ0.2). Patients with low ejection fraction (Յ30%) and severe AS had a higher 30-day post-PCI mortality compared with those with an ejection fraction Ͼ30% (5.4% [7 of 45] versus 1.2% [4 of 209]; PϽ0.001). In addition, AS patients with high Society of Thoracic Surgeons score (Ն10) had a higher 30-day post-PCI mortality than those with a Society of Thoracic Surgeons score Ͻ10 (10.4% [10 of 96] versus 0%; PϽ0.001). Conclusions-PCI can be performed in patients with severe symptomatic AS and coronary artery disease without an increased risk of short-term mortality compared with propensity-matched patients without AS. Patients with ejection fraction Յ30% and Society of Thoracic Surgeons score Ն10% are at a highest risk of 30-day mortality after PCI. This finding has significant implications in the management of severe coronary artery disease in high-risk severe symptomatic AS patients being considered for transcatheter aortic valve replacement. (N.S.P.). The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
A ortic stenosis (AS) is the commonest valve disease in the aging population [1] [2] [3] and often occurs concurrently with coronary artery disease (CAD). 4 -8 Surgical aortic valve replacement (SAVR) with concomitant coronary artery bypass grafting (CABG) has been the main treatment strategy for patients with severe symptomatic AS and CAD until recently. 9 Percutaneous coronary intervention (PCI) has therefore been performed infrequently in patients with severe AS and CAD, and the outcomes of PCI in patients with severe AS and severe CAD are largely unknown. With the availability of transcatheter aortic valve replacement (TAVR) as an alternative to SAVR, 10 -12 management of severe unrevascularized CAD in patients with severe AS is posing unique challenges, and PCI has been suggested as a way to improve procedural safety and outcomes of TAVR. 13, 14 
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Because CABG is considered the primary mode of revascularization in patients with CAD and severe AS, PCI is not performed in patients with severe AS. However, occasional patients with temporary or permanent contraindications to surgery are offered PCI if CAD is thought to be the cause of symptoms. Regardless of the reason for performing PCI, a systematic analysis of procedural outcomes of patients with severe AS who underwent PCI could provide useful information for the management of patients with severe CAD and AS who are referred for consideration for TAVR. With this in mind, we analyzed data from the Cleveland Clinic Interven-tional Registry to determine short-term outcomes of PCI in patients with severe AS.
Methods
The study population was obtained from the prospective interventional registry and the echocardiography database at the Cleveland Clinic. All patients who underwent a PCI at our institution between January 1, 1998, and December 31, 2008, were included. It is important to note that at our institution TAVR has been available under protocol in a limited number of patients only since the middle of 2006. Patients with severe AS (any one of the following on transthoracic echocardiography: aortic valve area Ͻ1.0 cm 2 , mean gradient Ͼ40 mm Hg, or jet velocity Ͼ4.0 m/s) 9 were identified from the echocardiography database. These patients with severe AS by echocardiography were matched with patients in the PCI database to identify 254 patients with severe AS who underwent PCI. Using propensity matching, we found 508 comparable patients without AS (controls) who underwent PCI. The methods for propensity matching are described in the Statistical Analysis section.
PCI was carried out in patients with severe AS for one or more of the following reasons: (1) clinical presentation of acute coronary syndrome (unstable angina, non-ST-segment-elevation myocardial infarction, or ST-segment-elevation myocardial infarction) and a diagnostic catheterization revealing a severe coronary lesion (defined as Ն70% stenosis) that was thought to be responsible for the presentation; (2) stable angina, the symptoms of which were thought to be attributable to significant CAD rather than AS by the patient's managing cardiologist or if the patient was deemed high risk for CABG and SAVR; and (3) the patient was thought to be high risk for SAVR by the managing team consisting of a cardiologist and a cardiac surgeon and the role of severe AS or severe CAD in the genesis of symptoms of New York Heart Association class III to IV congestive heart failure could not be differentiated.
Baseline characteristics, cardiac history, risk factors, medications, and angiographic and procedural data were prospectively obtained and recorded in the PCI registry by experienced research coordinators. Information on subsequent management of patients with severe AS, ie, SAVR or medical management, was obtained by chart review. The primary end point was all-cause mortality (at 30 days), which was assessed by querying the Social Security Death Index. Secondary end points were procedural complications, including contrast nephropathy (defined as Ն0.5 mg/dL or Ͼ25% increase in serum creatinine from baseline), periprocedural myocardial infarction (rise in creatine kinase-MB Ͼ3 times the upper limit of normal), procedural death, and hemodynamic compromise during PCI. The institutional review board waived requirements for informed consent for the institutional PCI registry.
Statistical Analysis
All statistical analyses were performed with Stata version 10.0 (StataCorp, College Station, TX). Propensity matching with logistic regression modeling was used to select matched controls with a case-to-control (AS-to-non-AS) ratio of 1:2. The patients were matched according to the propensity score (presented in Table I in the online-only Data Supplement), which included the following factors: age; sex; race; clinical characteristics like hypertension, diabetes, body mass index, dyslipidemia, chronic obstructive pulmonary disease, smoking, peripheral vascular disease, family history of CAD, stroke, renal failure, ejection fraction, serum hematocrit, and serum creatinine at the time of PCI; and lesion-related characteristics, including the number of vessels involved, number of vessels intervened, left main trunk disease, unprotected left main PCI, total lesion length, unstable angina, stable angina, non-ST-segmentelevation myocardial infarction, or ST-segment-elevation myocardial infarction. From these characteristics, a propensity score was calculated for each patient using the multivariate logistic regression model with "case/control" as the dependent variable. Using the calculated propensity score, we selected the 2 closest matches for each case. Standardized bias was compared between the unmatched and matched groups to verify the efficacy of this strategy in selecting well-matched controls.
Survival analysis comparing the cases and controls was conducted with the Kaplan-Meier method, and statistical comparisons were drawn with the log-rank test. Multivariable Cox proportional hazard modeling was used to determine the significant predictors of longterm mortality among patients with AS undergoing PCI. SAVR was hypothesized to be a significant predictor of favorable long-term mortality. Because SAVR in a patient was contingent on survival of the patient until the surgery, SAVR was included as a timedependent covariate in the Cox proportional hazard modeling. For each patient undergoing SAVR, the analysis time was modeled so that only the person-time after the surgery was included in the SAVR. The person-time before the occurrence of SAVR was included in the alternative no-SAVR category.
Results

Baseline Characteristics
A total of 254 patients with AS underwent PCI between January 1, 1998, and December 31, 2008, at the Cleveland Clinic. The control group was derived from a pool of 20 069 patients without AS who underwent PCI during the same time period. The baseline characteristics of 254 patients with severe symptomatic AS who underwent PCI and the propensity-matched group of 508 patients without AS who underwent PCI are shown in Table 1 . The effectiveness of the propensity matching is demonstrated in Figure 1 . We observed significant differences (measured with standardized biases) in several variables between the unmatched populations, which were subsequently eliminated effectively with the propensity matching. Tables 1 and 2 demonstrate that the 2 groups were well matched with respect to baseline, lesion, and interventional characteristics. The mean age was 75 years in both groups. Patients with severe AS had a mean Society of Thoracic Surgeons (STS) score of 13, with 38% of patients having an STS score of Ͼ10. The mean Logistic Euroscore of patients with AS was 32, with 61% of patients having a score Ͼ20.
Indications for PCI
Acute coronary syndrome (unstable angina in 41%, non-STsegment-elevation myocardial infarction in 19%, and STsegment-elevation myocardial infarction in 6%) was the indication for PCI in 66.5% of patients with severe AS and 58.6% of patients without AS (Table 1 ). In 24% of patients with severe AS, the indication for PCI was stable angina, and 43% of patients had congestive heart failure (New York Heart Association class III-IV). In this group of AS patients, the symptoms were thought to be more attributable to severe CAD rather than AS, the patients were deemed to be high risk for conventional SAVR and CABG, or both. The indications for PCI were well matched in patients with and without severe AS (Table 1) .
Short-Term Outcome After PCI
Thirty-day mortality after PCI was 4.3% (11 of 254) in patients with severe AS who underwent PCI compared with 4.7% (24 of 508; hazard ratio, 0.93; 95% confidence interval, 0.51-1.69; Pϭ0.2) in patients without severe AS who underwent PCI (Figure 2 ). In subgroup analysis of the severe AS group, patients with a low ejection fraction (Յ30%) had a higher 30-day post-PCI mortality of 15.4% (7 of 45) compared with 1.2% (4 of 209) among patients with AS and an ejection fraction Ͼ30% (PϽ0.001). In addition, patients with AS with a high STS score (Ն10) had a higher 30-day post-PCI mortality of 10.4% (10 of 96) compared with no mortality (0%) in those with AS and an STS score Ͻ10 (PϽ0.001).
Complications of PCI
Contrast nephropathy occurred in 6.7% of patients with severe AS compared with 4.7% patients in the non-AS group (Pϭ0.25). Other complications of PCI such as procedural death, hemodynamic compromise during PCI, periprocedural myocardial infarction, coronary dissection, coronary perforation, cardiac tamponade, access-site hematoma, and retroperitoneal bleed were not significantly different in the 2 groups, as shown in Table 3 .
Causes of 30-Day Post-PCI Mortality in AS Patients
Of the 11 patients with severe AS who died within a month after PCI, 82% (9 of 11) died in the hospital with progressive heart failure and multisystem organ failure. One patient had a cardiac arrest in the catheterization laboratory during PCI and could not be successfully resuscitated, and 1 patient was discharged from the hospital and readmitted to another hospital with pneumonia and died.
Long-Term Outcomes
At a mean follow-up of 3.7 years, 29% (73 of 254) of patients with severe AS had undergone SAVR, with a mean duration of 15.5Ϯ15.7 months between PCI and SAVR. In 37 of these 73 patients (51%), SAVR was performed within 1 year after PCI. Of the 73 patients who underwent SAVR, PCI was performed with drug-eluting stents in 27% (20 of 73) and with bare metal stents in 73% (53 of 73) of patients. CABG was performed with SAVR in 71% (52 of 73) of patients, and in the remaining 29% (21 of 73), CABG was not performed at the time of SAVR. The 30-day postoperative mortality in patients undergoing SAVR was 8% (6 of 73), and the 3-month mortality after SAVR was 14% (10 of 73). At a mean follow-up of 3.7 years, mortality was 42.5% (31 of 73) in AS patients who could undergo SAVR, 68% (123 of 181) in AS patients who could not undergo SAVR, and 46.7% (237 of 508) in the non-AS group. Compared with patients who were not able to undergo SAVR, patients who had SAVR were younger (age, 70Ϯ9 versus 77Ϯ9 years; PϽ0.0001) and had higher left ventricular ejection fraction (50Ϯ12% versus 44Ϯ14%; PϽ0.001), lower STS score (9.1Ϯ12.6 versus 14.2Ϯ14.8; PϽ0.01), lower Logistic Euroscore score (23.3Ϯ19.7 versus 35.9Ϯ22.7; PϽ0.0001), lower Additive Euroscore score (10.5Ϯ3.9 versus 12.6Ϯ3.7; PϽ0.0001), and less prevalence of New York Heart Association class III to IV heart failure (22% versus 51%; PϽ0.0001). In a multivariate Cox proportional hazard model (Table 4 ) incorporating surgical AVR as a timedependent covariate, we found that age, ejection fraction Յ30%, chronic kidney disease, diabetes mellitus, and chronic obstructive pulmonary disease were significant independent predictors of long-term mortality in patients with severe AS undergoing PCI.
Discussion
Our findings demonstrate that PCI can be performed in patients with severe AS and significant CAD without an increase in short term (30-day) mortality or procedural complication rate compared with a propensity-matched cohort of patients with significant CAD without AS undergoing PCI. However, patients with ejection fraction Յ30% and patients with STS score Ն10% are at highest risk of 30-day mortality after PCI.
Risk factors for AS have been found to be similar to those for atherosclerosis and CAD. 4 Significant CAD is often found in patients with severe AS, and its incidence increases with age of patients with AS; CAD has been reported in Ͼ50% of patients with AS who are Ն70 years of age and in Ͼ65% of patients who are Ն80 years of age. 15 Data on outcomes of PCI in patients with severe AS and severe CAD are very limited because PCI is uncommonly performed in such patients, primarily because patients with severe AS and CAD who are surgical candidates undergo concomitant CABG and SAVR. Two small studies in the literature have described the outcomes of PCI in patients with severe AS. Kuchulakanti et al 16 compared PCI outcomes in 28 patients with moderate AS, 28 patients with severe inoperable AS, and 55 patients with a history of AVR for AS and found no difference in short-term outcomes of PCI in these 3 groups; however, the longer-term outcomes were poorer in severe AS patients. In another study, Alcalai et al 17 described outcomes of 38 patients with AS who underwent PCI, but there were no control subjects in their population. Our study is different from these 2 smaller studies. We compared outcomes of PCI in 254 patients with severe symptomatic AS with a propensity-matched cohort of patients without AS who underwent PCI. Thus, we have a control group of patients who not only are matched with respect to baseline clinical features and procedural characteristics but also are without AS. Second, ours is a large cohort of patients with AS who underwent PCI over a 10-year period. The indications for PCI in these patients were mainly acute coronary syndrome, stable angina, or congestive heart failure when symptoms were thought by the managing physicians to be related mainly to CAD rather than AS or when patients were considered high risk for surgery by a team of physicians consisting of cardiologist and a cardiothoracic surgeon. We found no difference in the 30-day mortality and procedural complication rate after PCI in patients with and without severe AS. Contemporary risk prediction models for mortality after PCI have shown that multiple preprocedural clinical factors predict shortterm mortality and that angiographic variables provide only modest incremental benefit to the preprocedural clinical risk assessment. 18, 19 Concurrently, we found that LVEF Յ30%, increasing age, and the presence of renal failure, diabetes mellitus, and chronic obstructive pulmo-nary disease were predictors of poor outcome after PCI in patients with severe AS. The mean STS score of 13 and Logistic Euroscore score of 32 in our severe AS patient group were higher compared with those for patients in the recently published Placement of Aortic Transcatheter Valve Trial (PARTNER) trial, which is a testament to the truly high-risk nature of these patients. 10 Our findings are of great clinical relevance in today's era of TAVR. Patients with comorbidities such as old age, diabetes mellitus, chronic kidney disease, prior heart surgery, and chronic obstructive pulmonary disease with AS are being referred for TAVR. 20 Often, they have concurrent unrevascularized CAD. The optimal approach for managing CAD in these patients is unclear. It is recommended that management of CAD in patients undergoing TAVR should be an individualized decision based on the patient's clinical condition and anatomy. 13 However, the recently reported PARTNER trial excluded patients with substantial CAD requiring revascularization. 10 In the real world, these patients with concomitant significant CAD are being referred for TAVR. TAVR can be a high-risk procedure when performed in patients with significant CAD. Recently, Dewey et al 14 reported higher 30-day (13.1% versus 1.2%) and overall (35.7% versus 18.4%) mortality after TAVR (transfemoral or transapical approach) in patients with CAD compared with those without CAD (as defined by prior CABG or prior PCI). Significant CAD may be a marker for diffuse atherosclerosis and therefore sicker patients, who may also have greater procedural risks of TAVR. During TAVR, rapid pacing is performed during balloon inflation and during valve placement (in case of balloon-expandable devices), during which systemic blood pressure drops markedly, increasing the risk of ischemia and hemodynamic compromise in patients with significant unrevascularized CAD. Recently, the Multicenter Canadian Experience with TAVR showed that the need for hemodynamic support during TAVR with intra-aortic balloon counterpulsation or extracorporeal circulation owing to severe sustained hypotension or hemodynamic collapse was an independent predictor of early and late mortality after TAVR. 12 This risk is potentially higher in patients with unrevascularized severe CAD. Data on successful PCI after TAVR are very limited. 21, 22 However, this strategy of PCI after TAVR is not without risks. Valve struts may interfere with cannulation of coronaries, and catheter manipulation may potentially even dislodge the valve. Our results are particularly important for high-risk patients with severe AS with coexistent significant unrevascularized CAD who are being considered for TAVR. PCI in patients with significant CAD before TAVR can potentially reduce the procedural risk of TAVR and may reduce the need for revascularization after TAVR. In contrast to the study by Dewey et al, 14 a study by Masson et al 23 did not find an overall increased risk of adverse outcomes in patients with CAD after TAVR compared with those without CAD. However, in that study, consisting of 136 patients undergoing TAVR, the 30-day mortality after TAVR was almost twice as high in patients with CAD compared with those without CAD (11.5% versus 6.3%). This difference would likely be statistically significant in a larger population. In addition to the size, another limitation of that study was that 15 patients had undergone PCI before TAVR. Whether revascularization for bystander lesions not clearly causing ischemic symptoms is really necessary for patients with critical AS remains to be determined. Individualization of therapy based on comorbidities seems prudent because the risk of PCI increased in our study with greater comorbidities, particularly left ventricular ejection fraction Յ30% (Table 4 ), similar to PCI risk prediction models in patients without AS. 18 It was indeed sobering to find a 30-day mortality rate of 4.3% after PCI in patients with severe AS, which is similar to that in the highest-risk patients such as those with ST-segment-elevation myocardial infarction undergoing PCI, as indicated by the recent PCI risk prediction models. 18 Patients with severe AS undergoing PCI should therefore be considered high-risk PCI patients. On the basis of our data, if percutaneous revascularization is thought to be necessary in patients with severe AS, it can be performed without an increased risk of short-term mortality or procedural complications, especially in those with preserved left ventricular ejection fraction. Given the high mortality after PCI in those with reduced left ventricular ejection fraction, mainly as a result of progressive heart failure and multisystem organ failure, adjunctive balloon aortic valvuloplasty may have a role if aortic valve replacement is not feasible in a timely fashion.
Data from Ͼ10 000 patients undergoing heart surgery from the New York Cardiac Surgery Reporting System showed that mortality for isolated valve surgery was 4.4% compared with 8.9% for valve surgery and concomitant CABG. 24 Consequently, hybrid minimally invasive valve surgery and concomitant PCI have been proposed in patients with poor conduit for CABG, high-risk patients presenting with acute coronary syndrome and known valve disease, and patients presenting for valve re-replacement in the setting of CAD. 25, 26 In this light, our study provides reassuring data that PCI can be carried out in the short term in patients with severe AS without an increase in mortality compared with propensity-matched patients without AS. Thus, a higher-risk combined valve/CABG procedure can be converted into 2 potentially lower-risk procedures, ie, PCI for CAD and isolated AVR with a minimally invasive approach. However, with hybrid procedures, there is a risk of bleeding after PCI in the presence of dual antiplatelet therapy and a risk of stent thrombosis in the absence of antiplatelet agents. Antiplatelet strategies will need to be evaluated in future studies before hybrid valve/PCI procedures can be considered. In addition, with such an approach, patients should not have to wait too long after PCI before AVR (surgical or transcatheter). In our study, more than half the patients with AS (37 of 73) who were able to undergo SAVR did so within 1 year after their PCI, and by 2 years after PCI, most of these patients had undergone SAVR. This is important because it is well known from natural history studies of AS that after the onset of symptoms, average survival without definitive therapy is 2 to 3 years with a high risk of sudden death. 9 *Other predictors included in the model but found to be insignificant: race, male sex, body mass index, history of smoking, peripheral arterial disease, hypertension, hyperlipidemia, stroke, presence of severely calcified coronary arteries, chronic total occlusion, ostial lesions, American College of Cardiology score C, and total lesion length.
The present study has limitations in that it is an observational, single-center study and is prone to bias, although we tried to minimize bias with propensity matching. This is the largest such study to date comparing patients with and without severe AS undergoing PCI. Frailty was not recorded in patient records in an objective fashion until recently, and this could be a confounder, leading to patients with severe AS being considered high risk for SAVR. TAVR studies have only recently started using standardized definitions for frailty. 27 About 22% patients in each group underwent PCI with drug-eluting stents; thus, the majority of patients underwent PCI with bare metal stents, making this largely a bare metal stents study. Our aim, however, was not to compare outcomes with different types of stents but to assess the safety of PCI in a wide variety of clinical presentations in patients with severe symptomatic AS and significant CAD in the real world and its implications on the management of severe CAD in the setting of TAVR.
Conclusions
PCI can be performed in patients with severe symptomatic AS without increased risk of short-term mortality or procedural complications compared with propensity-matched patients without AS. Patients with ejection fraction Յ30% and STS score Ն10% are at a highest risk of 30-day mortality after PCI. This finding has significant implications in the management of severe CAD in high-risk, severely symptomatic AS patients being considered for TAVR and other minimally invasive surgical options.
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